Scolaris Content Display Scolaris Content Display

Smoking cessation for the secondary prevention of coronary heart disease

This is not the most recent version

Abstract

Background

Although the importance of smoking as a risk factor for coronary heart disease is beyond doubt, the speed and magnitude of risk reduction when a smoker with coronary heart disease quits are still subjects of debate.

Objectives

To estimate the magnitude of risk reduction when a patient with CHD stops smoking.

Search methods

We searched the Cochrane Register of Controlled Trials (CENTRAL) , MEDLINE, EMBASE, Science Citation Index, CINAHL, PsychLit, Dissertation Abstracts, BIDS ISI Index to Scientific and Technical Proceedings, UK National Research Register from the start of each database. Sixty‐one large international cohort studies of cardiovascular disease were identified, and contact made with authors to search for any unpublished results. The search was supplemented by cross‐checking references and contact with various experts. Date of last search was April 2003.

Selection criteria

Any prospective cohort studies of patients with a diagnosis of CHD, which include all‐cause mortality as an outcome measure. Smoking status must be measured on at least two occasions to ascertain which smokers have quit, and followed‐up for at least two years.

Data collection and analysis

Eligibility and trial quality were assessed independently by two reviewers.

Main results

Twenty studies were included. There was a 36% reduction in crude relative risk (RR) of mortality for those who quit smoking compared with those who continued to smoke (RR 0.64, 95% confidence interval (CI) 0.58 to 0.71). There was also a reduction in non‐fatal myocardial infarctions (crude RR 0.68, 95% CI 0.57 to 0.82). Many studies did not adequately address quality issues, such as control of confounding, and misclassification of smoking status. However, there was little difference in the results for the six 'higher quality' studies, and little heterogeneity between these studies. This review was not able to assess how quickly the risk of mortality was reduced.

Authors' conclusions

Quitting smoking is associated with a substantial reduction in risk of all‐cause mortality among patients with CHD. The pooled crude RR was 0.64 (95% CI 0.58 to 0.71). This 36% risk reduction appears substantial compared with other secondary preventive therapies such as cholesterol lowering which have received greater attention in recent years. The risk reduction associated with quitting smoking seems consistent regardless of differences between the studies in terms of index cardiac events, age, sex, country, and time period. However, relatively few studies have included large numbers of older people, women, or people of non‐European descent, and most were carried out in Western countries.

PICOs

Population
Intervention
Comparison
Outcome

The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.

See more on using PICO in the Cochrane Handbook.

Plain language summary

People who quit smoking after a heart attack or cardiac surgery reduce their risk of death by at least one third

Smoking is harmful for the heart and circulation. People who have had a heart attack or cardiac surgery are at increased risk of further life‐threatening heart problems, including death from heart attack. The review found strong evidence that quitting smoking after a heart attack or cardiac surgery can decrease that person's risk of death by at least one third. The beneficial impact of quitting smoking after serious heart disease may be as great or greater than other possible interventions (such as cholesterol‐lowering medications).